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Abstract
Background: Many state Medicaid programs are implementing pharmacist-led medication management programs
to improve outcomes for high-risk beneficiaries. There are a limited number of studies examining implementation
of these programs, making it difficult to assess why program outcomes might vary across organizations. To address
this, we tested the applicability of the organizational theory of innovation implementation effectiveness to examine
implementation of a community pharmacy Medicaid medication management program.
Methods: We used a hurdle regression model to examine whether organizational determinants, such as implementation
climate and innovation-values fit, were associated with effective implementation. We defined effective implementation in
two ways: implementation versus non-implementation and program reach (i.e., the proportion of the target population
that received the intervention). Data sources included an implementation survey administered to participating
community pharmacies and administrative data.
Results: The findings suggest that implementation climate is positively and significantly associated with implementation
versus non-implementation (AME = 2.65, p < 0.001) and with program reach (AME = 5.05, p = 0.001). Similarly, the results
suggest that innovation-values fit is positively and significantly associated with implementation (AME = 2.17, p = 0.037)
and program reach (AME = 11.79, p < 0.001). Some structural characteristics, such as having a clinical pharmacist on staff,
were significant predictors of implementation and program reach whereas other characteristics, such as pharmacy type
or prescription volume, were not.
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Conclusions: Our study supported the use of the organizational theory of innovation implementation effectiveness to
identify organizational determinants that are associated with effective implementation (e.g., implementation climate and
innovation-values fit). Unlike broader environmental factors or structural characteristics (e.g., pharmacy type), implementation
climate and innovation-values fit are modifiable factors and can be targeted through intervention—a finding
that is important for community pharmacy practice. Additional research is needed to determine what implementation
strategies can be used by community pharmacy leaders and practitioners to develop a positive implementation climate
and innovation-values fit for medication management programs.
Keywords: Implementation climate, Innovation-values fit, Community pharmacy, Medication management,
Organizational theory
Background
Many state Medicaid programs have expanded enrollment
eligibility under the Affordable Care Act, making Medic-
aid the largest health insurance program in the USA [1, 2].
Medicaid spending is largely driven by a small subset of
high-risk patients; 5 % of Medicaid beneficiaries account
for almost half of Medicaid expenditures [3]. This small
subset of beneficiaries is disproportionately impacted by
chronic conditions, such as diabetes and asthma, and the
co-occurrence of difficult-to-treat conditions (e.g., sub-
stance use and mental health conditions) [3]. To improve
chronic disease management, several Medicaid programs
have implemented medication management programs in
partnership with pharmacists [4–6].
Pharmacist-led medication management programs have
improved patients’ medication adherence and therapeutic
outcomes (e.g., blood pressure, hemoglobin A1C) while
reducing healthcare costs [7–10]. However, researchers
have had difficulty attributing changes in patient out-
comes to specific program features due to the wide vari-
ability in medication management programs [4, 11]. In the
Medicare Part D Medication Therapy Management
(MTM) program, for example, researchers have noted that
medication services are delivered in a variety of settings
(e.g., call centers, outpatient care) and formats (e.g.,
in-person vs. phone) [11]. Similar challenges exist in
Medicaid medication management programs—programs
vary in patient eligibility criteria, the services provided,
and the setting of service delivery [4].
In addition to program design variability, there are a
limited number of studies examining implementation of
pharmacist-led medication management programs, mak-
ing it difficult to assess why program outcomes might
vary across organizations. Many of the studies that have
examined organizational determinants of implementa-
tion effectiveness in pharmacist-led medication manage-
ment programs have been qualitative, limiting their
generalizability, or have not been guided by a theory,
making it difficult to interpret the findings. Past studies
have identified factors, such as organizational structure
(e.g., staff size), leadership support, and financial resource
availability [12–16], but not applied theory to demonstrate
how these factors work in concert to produce effective
implementation. Thus, this study will test the applicability
of the organizational theory of innovation implementation
effectiveness to examine implementation of a community
pharmacy Medicaid medication management program.
Conceptual framework
Implementation theories have been developed to identify
the organizational factors and underlying relationships that
are hypothesized to influence effective implementation (i.e.,
the quality and consistency of implementation) [17, 18].
The organizational theory of innovation implementation
effectiveness was designed for complex innovations like
medication management programs, which often re-
quire coordinated use by multiple individuals to be
effective [18–20]. This theory posits that effective im-
plementation is driven by an organization’s implemen-
tation climate and the fit between the innovation and
organization values (Fig. 1) [18–20]. For example, a
community pharmacy might develop formal policies
to support implementation of a medication management
program such as employee training or reward and
recognition systems. The collective influence of the phar-
macy’s implementation policies, in turn, affects employees’
shared perceptions about the extent to which the medica-
tion management program is rewarded, supported, and
expected (implementation climate) [18–20]. Positive per-
ceptions about implementation climate are likely to in-
crease employees’ acceptance of medication management
programs, increasing the likelihood that pharmacy staff
will appropriately implement medication management
programs (i.e., as the pharmacy intended for it to be
implemented) and ultimately increase implementation
effectiveness. Therefore, we hypothesize that positive per-
ceptions about implementation climate will be positively
associated with implementation effectiveness (H1).
The organizational theory of innovation implementa-
tion effectiveness maintains that innovation-values fit
also affects implementation effectiveness [18–20]. In this
specific case, innovation-values fit refers to pharmacy
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employees’ perceptions about how well medication man-
agement programs align with the values of the pharmacy
and the pharmacy profession. Innovation-values fit is be-
lieved to affect implementation effectiveness both dir-
ectly and indirectly. If pharmacy employees perceive that
medication management programs do not align with the
pharmacy’s values, the employee may be less committed
to implementation and exert less effort towards ensuring
effective implementation [18]. Innovation-values fit is
also likely to impact the relationship between implemen-
tation climate and implementation effectiveness [18–20].
Since innovation-values fit affects commitment, the im-
pact of implementation climate on implementation ef-
fectiveness will be amplified by positive, and weakened
by negative, perceptions about innovation-values fit.
Thus, we hypothesize that positive perceptions about
innovation-values fit will directly and positively affect
implementation effectiveness (H2) and moderate the
relationship between implementation climate and imple-
mentation effectiveness (H3).
Implementation effectiveness is also likely to be affected
by broader environmental and organizational factors (e.g.,
organizational context), such as patient needs and re-
sources, available resources, access to knowledge about
the intervention, and structural characteristics [21]. For
example, community pharmacies that serve a higher pro-
portion of high-risk patients may be better at implement-
ing innovations for high-risk populations. Additionally,
pharmacies in rural locations may be better at implement-
ing innovations for high-risk populations since residents
in rural areas have higher rates of chronic illness [22].
Implementation effectiveness is also likely to be positively
influenced by a pharmacy’s available resources, such as
amount of staff and training of staff, and access to know-
ledge about medication management programs (e.g.,
experience implementing similar interventions). Con-
versely, certain structural characteristics may negatively
affect implementation effectiveness. For example, pharma-
cies that have opened recently may not have as strong of
ties with patients as pharmacies that have been in oper-
ation for many years (e.g., the liability of newness hypoth-
esis) [23]. Similarly, larger pharmacies may be impeded by
a more formal organizational structure, which can
negatively impact innovation implementation [24]. For in-
stance, managers of independently owned pharmacies
may have greater decisional autonomy because there is
less formalization in the organization and, as a result, be
better able to support implementation of medication man-
agement programs. Therefore, we hypothesize that four
contextual factors, patient needs and resources, available
resources, access to knowledge about the intervention,
and structural characteristics, will affect implementation
effectiveness (H4).
Methods
Study design
We used a cross-sectional design examining implemen-
tation of a community pharmacy Medicaid medication
management program during the program year of 2016.
The unit of analysis was at the pharmacy level.
Innovation-values fit  
(Perception of how well the 
innovation fits with mission of 
the organization and 
profession) 
Organizational context 
(Broader environmental and
organizational factors including 
patient needs and resources, 
available resources, access to 
knowledge about the 
intervention, and structural 
Implementation climate 
(Perception of the extent to 
which the innovation is 
supported, rewarded, and 
expected) 
Implementation 
effectiveness 
(The quality and consistency of
implementation)
Fig. 1 The impact of implementation climate and innovation-values fit on implementation effectiveness
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Intervention description
The community pharmacy enhanced services network
(CPESNSM) is a national network of community pharma-
cies that offer medication management services [25]. This
study examines the North Carolina CPESN (NC-CPESN),
the pioneer site for CPESN [6]. NC-CPESN was launched
in 2014 by the Community Care of North Carolina
(CCNC)—the primary case management provider for NC
Medicaid beneficiaries [6, 26]. NC-CPESN is voluntary
and allows any community pharmacy if the following
requirements are met: (1) provide certain medication
management services, (2) be responsible for the outcomes
of a defined patient population through value-based pay-
ment, and (3) tailor services based on patients’ risk score.
One of the key services required for reimbursement is a
comprehensive medication review (CMR) to identify
opportunities for improving medication management and
reduce risk of medication problems. Patients include
Medicaid, Medicare, and NC Health Choice beneficiaries,
as well as dual-eligible patients. The payment model is a
per-member per-month payment model based on patient’s
risk score (described below) and the pharmacy’s perform-
ance score on a series of measures including medication
adherence, total cost of care, hospital admission rate, and
emergency department admissions [27].
Study population
The study population included community pharmacies
that participated in either the first year or the second
year of the 3-year NC-CPESN program (September
2014–August 2017); pharmacies that joined in the third
year were excluded from the analysis because they had
little-to-no experience with implementation at the time
of the survey (described below).
Data sources
In fall 2016, we administered a paper-based survey to
community pharmacies that participated in either the first
or second year of the NC-CPESN program. The survey
assessed pharmacies’ structural characteristics, experience
with NC-CPESN, and perceptions about implementation
(e.g., implementation climate, innovation-values fit). A
copy of the survey has been published elsewhere [28]. A
committee of researchers and community pharmacy prac-
titioners (n = 25) reviewed the survey items’ content, read-
ability, and formatting. The survey questions were also
piloted in a small group of community pharmacists (n = 5)
who were identified as experts by the committee based on
their job tenure and reputation in the field of community
pharmacy. From the committee review and the initial pilot
test, we received similar types of feedback and felt that
further pilot testing was not needed. The survey was
mailed to participating pharmacies along with other
NC-CPESN program materials to increase the response
rate. Pharmacies also received three email reminders
at ~ 2, 4, and 8 weeks after the survey was mailed.
Within the pharmacy, employees that were intended
users of NC-CPESN (e.g., pharmacists, pharmacy
technicians, and administrative staff ) completed the
survey. We did not include supporters of NC-CPESN
(e.g., pharmacy owners who supported the intervention
through policies and resources but did not directly imple-
ment the intervention) since their actions indirectly rather
than directly affect implementation, a decision that is con-
sistent with other implementation studies [19, 29]. We
had more than one respondent per pharmacy; therefore,
the responses were aggregated to the pharmacy level (de-
scription below). We received surveys from 191 of 268
pharmacies (71.3% response rate). Participants provided
written consent. The Institutional Review Board of the
University of North Carolina at Chapel Hill approved this
study (IRB # 17-1304).
In addition, we used 2016 NC-CPESN program adminis-
trative data and 2016 county health ranking data [30]. Pro-
gram administrative data provided information on the
number of high-risk patients attributed to each pharmacy,
patient demographics, and the number of CMRs that were
delivered. County health ranking data included county-level
measures of clinical (e.g., healthcare access) and social (e.g.,
insurance status) factors that might affect the pharmacy’s
implementation of NC-CPESN [30]. The operationalization
of these measures is described below.
Dependent variables
We used two variables to measure implementation
effectiveness—one indicator for implementation ver-
sus non-implementation and one indicator for pro-
gram reach.
Implementation of a CMR for high-risk patients
Based upon whether a pharmacy implemented a CMR
on any attributed high-risk patient, we divided the sam-
ple into implementers (e.g., ≥ 1 CMR for an attributed
high-risk patient) and non-implementers (e.g., no CMR
for any attributed high-risk patients) during the program
quarter Nov. 2016–Jan. 2017. We chose this quarter be-
cause there were no changes to the intervention (e.g.,
intervention requirements or payment model) during
this or the previous quarter. High risk was defined as
having a care triage score ≥ 75. Care triage score is a pro-
prietary measure used by CCNC to estimate a patient’s
risk for hospitalization and includes variables such as
the number of chronic conditions a patient has and the
type of medication the patient is taking. Patients with
care triage scores > 75 are considered a priority popula-
tion for CCNC. Patients are defined as attributed to a
pharmacy if they filled at least one chronic medication
within the last 90 days and ≥ 80% of their medications
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for at least two of 3 months within the quarter. Patients
also had to be eligible for Medicaid or Medicare for at
least two of the 3 months within the quarter. The
patient attribution process is done on a monthly basis.
On average, in any given month, about 100,000 NC resi-
dents are attributed to NC-CPESN pharmacies [27].
Proportion of high-risk patients receiving a CMR
We measured implementation effectiveness to assess the
reach of the intervention among attributed high-risk pa-
tients. We calculated the number of attributed high-risk
patients receiving a CMR divided by the number of
high-risk, attributed patients per pharmacy during the
program quarter Nov. 2016–Jan. 2017.
Independent variables
Implementation climate
Implementation climate was defined using four survey
items assessing the extent to which NC-CPESN was sup-
ported, rewarded, and expected within the pharmacy (e.g.,
“Our pharmacy allocates sufficient time to delivering en-
hanced pharmacy services” and “Our pharmacy devotes
adequate resources to implementing enhanced pharmacy
services”) [18–20]. The survey items were adapted for a
pharmacy setting from a scale validated in an oncology
setting [31, 32]. The questions included group rather than
individual referents, which is recommended when asses-
sing organizational-level outcomes such as implementa-
tion climate [29]. Each item was measured on 5-point
Likert scale ranging from 0 (strongly disagree) to 4
(strongly agree). The survey items were summed for indi-
vidual staff members who worked directly on implementa-
tion (i.e., innovation users), and a mean was calculated to
produce a pharmacy-level measure. Higher values of the
score corresponded with positive perceptions of imple-
mentation climate.
Innovation-values fit
Innovation-values fit was defined using four survey
items assessing staff perceptions about the extent to
which NC-CPESN fit with the values of the pharmacy
(e.g., “Delivering enhanced pharmacy services is consist-
ent with providing the best care possible for our pa-
tients”) and of the pharmacy profession (“Delivering
enhanced pharmacy services is important for advancing
the field of pharmacy”) [18–20]. To identify “high-inten-
sity” values, or values that are highly important to phar-
macy staff, we obtained pharmacy practitioner input
during the survey pilot (described above) [18–20]. For ex-
ample, practitioners described the importance of improv-
ing the quality of services across all community
pharmacies, not just the quality of services within their
own pharmacy. As a result, practitioners described valuing
interventions that would advance the field of community
pharmacy as a whole. To address this, we included a sur-
vey item to assess perceptions about whether NC-CPESN
was advancing the field of pharmacy. As with implementa-
tion climate, the innovation-values fit questions were
group-referenced, measured on the same 5-point Likert
scale, aggregated from individual responses to produce a
pharmacy-level mean, and ordered so that higher scores
corresponded to positive perceptions.
Other independent variables
Patients’ needs and resources were measured by rural lo-
cation, clinical factors, social factors, 340B participation,
and proportion of high-risk patients. Rural location was
defined as a binary variable (e.g., urban, rural) using a zip
code approximation of the rural-urban commuting area
codes. Clinical factors were defined using a pre-existing,
county-level composite measure of access to care items
(e.g., primary care provider ratio, uninsured rate) and
quality of care items (e.g., preventable hospital stays, dia-
betes monitoring) ranging from 0 to 100 [30]. Social fac-
tors were defined using a pre-existing, county-level
composite measure of items such as education, employ-
ment, uninsured, and income ranging from 0 to 100 [30].
The clinical and social factor scales were recoded so that
higher values on the scale were associated with better
patient outcomes. Participation in 340B Drug Pricing
Program was measured as a binary variable. The 340B
Drug Pricing Program is a federal program that requires
drug manufacturers to provide outpatient drugs to eligible
healthcare organizations (e.g., safety net providers) at a
discounted rate [33]. Community pharmacies can partici-
pate in this program by dispensing 340B drugs through a
contract with eligible healthcare organizations. Proportion
of high-risk patients was defined as the number of
attributed high-risk patients divided by the number of
attributed patients per pharmacy over a program quarter.
Available resources
Available resources were measured by three variables:
the presence of a clinical pharmacist (binary), total num-
ber of full- and part-time staff (e.g., pharmacists, phar-
macy technicians, administrative staff ), and the presence
of pharmacy students or residents in the past month
(binary). A clinical pharmacist is defined as a pharmacist
whose role focuses not only on dispensing medication
but also on the clinical care of patients, such as optimiz-
ing patients’ medication regimens and providing health
education and preventive health services [34]. In com-
munity pharmacies, a clinical pharmacist typically has
some or all of their time devoted to activities outside of
dispensing medications, such as delivering medication
management services [35]. The role of clinical pharma-
cist, such as the type of clinical services offered within
the pharmacy, as well as the amount of time devoted to
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non-dispensing activities, varies, however, across com-
munity pharmacy settings.
Access to knowledge about the intervention
Access to knowledge about the intervention was measured
in three ways: (1) experience with NC-CPESN, defined as
the number of months the pharmacy was enrolled in
NC-CPESN; (2) past performance with NC-CPESN, mea-
sured using a lagged dependent variable (e.g., proportion
of CMRs completed per high-risk patients) for the previ-
ous program quarter (Aug–Oct 2016); and (3) participa-
tion in Medicare Part D MTM (binary).
Structural characteristics
Structural characteristics were assessed by three variables.
First, independent ownership was a binary variable: single-
and multiple- independent pharmacies versus chain, out-
patient, and federally qualified health center (FQHC)
pharmacies. Independently owned pharmacies include
single-independent pharmacies (i.e., an owner owns one
pharmacy) and multiple independent pharmacies (i.e., an
owner owns multiple pharmacies). Chain pharmacies in-
clude pharmacies owned by a publically traded company.
Outpatient pharmacies are pharmacies operated by a
health system and located within an outpatient healthcare
setting (e.g., primary care office), and FQHC pharmacies
are operated by and located within a FQHC. We used a
binary variable due to small sample sizes within the chain
and outpatient pharmacy categories. Second, prescription
volume was dichotomized as low (< 2000 prescriptions/
week) versus high (≥ 2000 prescriptions/week). The criter-
ion for low volume was selected based on input of
community pharmacy practitioners and researchers.
Third, established pharmacies were those that had been in
operation for more than 20 years. Similarly, the threshold
of 20 years as the criterion for established pharmacy was
selected based on input from community pharmacy
practitioners and researchers.
Statistical analysis
Descriptive statistics
Frequencies and percentages were used to describe the
study population. We conducted bivariate analyses to
compare the sample characteristics between implementers
(completed ≥ 1 CMR during the program quarter for
high-risk patients) and non-implementers (no completed
CMR during the program quarter for high-risk patients).
Exploratory factor analyses
To determine if implementation climate and
innovation-values survey items could be used as dis-
tinct variables, we conducted three analyses. First, we
examined pairwise correlations among the items and
conducted a Bartlett’s test of sphericity and a
Kaiser-Meyer-Olkin (KMO) test. Second, we defined
the number of initial factors using principal compo-
nent analysis and rotated the factors using orthogonal
varimax rotation to improve interpretability. Finally,
we confirmed the number of extracted factors using
two decision rules: (1) the number of eigenvalues > 1.0,
and (2) the number of eigenvalues from the factor ana-
lysis that were larger than the eigenvalues from ran-
domly generated data (e.g., parallel analysis test). We
also assessed the internal consistency of the two scales
using Cronbach’s coefficient alpha. To ensure the re-
sults were not overly sensitive to the method of factor
extraction, we conducted a sensitivity analysis by run-
ning a common factor analysis using principal axis fac-
toring and did not find differences in the results. We
also compared the results of the exploratory factor
analyses by staff roles within pharmacies (e.g., pharma-
cists, pharmacy technicians, and administrative staff )
to determine if results from different staff types could
be aggregated to the pharmacy level. Factor analyses
did not differ by subgroup, suggesting that aggregating
subgroups was appropriate.
Hurdle regression model
Hurdle regression is a two-equation model for count
data: one equation determines the likelihood of an out-
come (e.g., whether a pharmacy implemented a CMR)
and the other examines the positive outcomes (e.g., how
many CMRs were delivered to high-risk patients) [36, 37].
We used a hurdle regression to model both of these pro-
cesses and to account for an excess of zeroes in the
dependent variable (40.8% of the sample had zero imple-
mentation in the program quarter). For the first stage, we
used a logistic regression to determine the probability of a
pharmacy implementing a CMR for a high-risk patient
(e.g., implementer versus non-implementer). For the sec-
ond stage, we used a zero-truncated negative binomial
model to determine how many CMRs were delivered to
high-risk patients (e.g., program reach). A negative bino-
mial model was selected over a Poisson model to account
for over-dispersion in the data (i.e., the variance was larger
than the mean). For the negative binomial model, we
treated the denominator (i.e., number of high-risk pa-
tients) as the exposure to adjust for differences in the
opportunity available to deliver the intervention and
assumed the unobserved heterogeneity was gamma
distributed (i.e., NB2 model). We compared this
model with a zero-inflated negative binomial, which is
another two-equation model for count data; we did
not find differences in the results. Therefore, we used
the hurdle regression.
In the hurdle regression, we included the key variables of
interest (e.g., implementation climate, innovation-values fit,
and an interaction of the two) and control variables selected
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a priori (e.g., patient needs and resources, available re-
sources). We assessed the goodness of fit for the interaction
term in both stages of the model since interpretation of
marginal effects on interaction terms can be complicated in
non-linear models [38]. Since the interaction term im-
proved fit in both stages, we included the term. To model
the impact of the interaction term, we plotted the marginal
effect of innovation-values fit over representative values of
implementation climate score for both of the equations.
One control variable, past performance with NC-CPESN,
was a lagged dependent variable, which can cause biased
coefficients if the data generating process is non-stationary
[39]. Using the Harris-Tzavalis test [40], which can be used
when the number of time periods is small relative to the
number of panels, we rejected the null hypothesis that the
data generating process is non-stationary. Therefore, we in-
cluded the lagged dependent variable in the model. We
used cluster-robust standard errors to account for cluster-
ing that might occur at the network level. NC-CPESN
pharmacies are grouped into regional networks by CCNC
and may receive different levels and quality of implementa-
tion support across networks. All pharmacies received stan-
dardized training on how to document a CMR and how to
use the documentation system that was required by
NC-CPESN; however, the amount and type of technical as-
sistance to support implementation of NC-CPESN (e.g.,
how to deliver a CMR) varied across networks [41]. Be-
cause the amount of missing data in both equations of the
model was less than 10% (8.0 and 5.8%, respectively), we
addressed missingness using complete case analysis. To
test whether missingness might be correlated with the
dependent variable, we compared the proportion of imple-
menters and non-implementers between survey respon-
dents and non-respondents and did not find significant
differences (X 2 ¼ 2:27, p = 0.132). We conducted the ana-
lyses using Stata version 13.0 (College Station, TX).
Results
Of the 191 pharmacies in our sample, 113 (59.16%) were
implementers. Pharmacies that successfully implemented a
CMR had a significantly higher mean implementation cli-
mate (11.81 vs. 3.55, p < 0.001) and innovation-values fit
(13.55 vs. 11.06, p < 0.001) scores (Table 1). In terms of pa-
tient needs and resources, implementing pharmacies were
significantly more likely to participate in the 340B Drug
Pricing Program (69.12 vs. 30.88%, p = 0.024) and have a
higher proportion of high-risk patients (0.42 vs. 0.36,
p = 0.004). For available resources, implementing phar-
macies were more likely to have a clinical pharmacist
(86.49 vs. 13.51%, p < 0.001) and either a pharmacy stu-
dent or resident on staff (92.86 vs. 7.14%, p < 0.001).
Implementing pharmacies had more experience with
NC-CPESN (34.37 vs. 27.05 months, p < 0.001) and had a
higher proportion of CMRs performed among high-risk
patients in the previous quarter (0.03 vs. 0.00, p < 0.001).
For structural characteristics of pharmacies, we did not
find any significant differences between implementers and
non-implementers.
Exploratory factor analysis
All pairwise correlations among the items in the imple-
mentation climate and innovation-values scales were
greater than 0.30, indicating there was sufficient correl-
ation for factor analysis (Table 2). Further, none of the
pairwise correlations exceeded > 0.80, indicating that
high multicollinearity was not a problem. The Bartlett’s
test of sphericity was significant for the implementation cli-
mate (X2 ¼ 1975:43; p < 0:001Þ and the innovation-values
fit scale (X2 ¼ 1077:83; p < 0:001Þ. Therefore, we rejected
the null hypothesis that either matrix was an identity
matrix. The KMO statistic for implementation climate and
innovation-values fit scales was 0.773 and 0.818,
respectively, which are within an acceptable range to sup-
port factor analysis (greater than 0.60) [42].
Factor loadings produced from the principal component
analysis (Table 3) suggest that survey items measuring im-
plementation climate or innovation-values fit load onto
two distinct factors. For each set of items, only one factor
had an eigenvalue exceeding 1.0 (implementation climate,
largest EV = 2.77; innovation-values fit, largest EV = 3.35),
and these eigenvalues were greater than eigenvalues from
a randomly generated data set, suggesting one factor
should be extracted for each set of items. The total
amount of variance in the items explained by the two ex-
tracted factors was 79.27% for implementation climate
and 83.63% for innovation-values fit. There were several
items that had double factor loadings (e.g., loaded onto
more than one factor) (Table 3); however, based on our
decision rules as well as our theory, we retained one ex-
tracted factor for each set of items. Cronbach’s coefficient
alpha was 0.845 for the implementation climate scale and
0.833 for the innovation-values scale, suggesting the items
have “very good” internal consistency [43].
Hurdle regression: equation 1
Hypothesis 1
The first equation of the hurdle regression indicated that a
one-unit increase in the implementation climate score in-
creased the probability of NC-CPESN implementation by
2.65 percentage points holding all else constant (p < 0.001)
(Table 4). The predicted probability of NC-CPESN imple-
mentation for pharmacies with the median implementa-
tion climate score (9.14) was 0.66 compared to 0.84 for
pharmacies with an implementation climate score at the
75th percentile (12.50).
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Hypothesis 2
Similarly, an increase in innovation-values fit score in-
creased the probability of NC-CPESN implementation
by 2.17 percentage points (p = 0.037). The predicted
probability of NC-CPESN implementation for pharma-
cies with the median innovation-values score (13.07) was
0.61 compared to 0.66 for pharmacies with an imple-
mentation climate score at the 75th percentile (14.68).
Hypothesis 3
The marginal effect of innovation-values fit on the prob-
ability of NC-CPESN implementation increased as imple-
mentation climate score increased. The marginal effect
began to decline at an implementation score of 8 (Fig. 2).
Hypothesis 4
No significant differences in the probability of
NC-CPESN implementation was found based on pa-
tients’ needs and resources. For available resources, the
probability of implementing NC-CPESN was 9.86 per-
centage points higher for pharmacies that had a clinical
pharmacist (p = 0.038). In terms of access to knowledge
about the intervention and available resources, amount
of experience with NC-CPESN (p = 0.004), past perform-
ance with NC-CPESN (p < 0.001), and participation in
Medicare Part D MTM (p = 0.003) were each positively
associated with the probability of implementing
NC-CPESN. Within structural characteristics, the prob-
ability of implementing NC-CPESN was 4.14 percentage
Table 1 Descriptive statistics of community pharmacies participating in NC-CPESN
Characteristics Implementers (n = 113)
Mean (SD) or %
Non-implementers (n = 78)
Mean (SD) or %
Total (n = 191)
Mean (SD) or %
Range
Key independent variables
Implementation climate 11.81 (3.0252) 3.55 (3.064)*** 8.37 (5.087) 0–16
Innovation-values fit 13.55 (2.0218) 11.06 (3.99)*** 12.51 (3.231) 0–16
Patient needs and resources
Rural location 57.78 42.22 23.56 0–1
Clinical factors 31.94 (29.78) 39.63 (29.40) 35.08 (29.8) 1–100
Social factors 44.07 (30.8) 46.36 (33.17) 45.01 (31.8) 1–100
340B participation 69.12 30.88* 36.76 0–1
Proportion of high-risk patients 0.42 (0.14) 0.36 (0.18)** 0.40 (0.16) 0–0.87
Available resources
Presence of a clinical pharmacist 86.49 13.51*** 19.37 0–1
Total number of staff 12.83 (6.464) 11.53 (8.827) 12.30 (7.525) 1–40
Presence of pharmacy student or resident 92.86 7.14*** 21.99 0–1
Access to knowledge about the intervention
Amount of experience with NC-CPESN (months) 34.37 (7.0546) 27.05 (7.96)*** 31.38 (8.249) 12.1–44.7
Past performance with NC-CPESN 0.03 (0.04) 0.00 (0.00)** 0.02 (0.0) 0–0.31
Participation in Medicare Part D MTM 67.27 32.73*** 86.39 0–1
Structural characteristics
Independent pharmacy 57.83 42.17 43.46 0–1
Low prescription volume 56.06 43.94 34.55 0–1
Established pharmacy 45.13 30.77 39.27 0–1
Significance of t tests or Pearson’s chi-square tests comparing implementers to non-implementers: *p < 0.05, **p < 0.01, ***p < 0.001
Table 2 Correlation matrix for the implementation climate and innovation-values fit scales
Item Implementation climate Item Innovation-values fit
1 2 3 4 1 2 3 4
1 Support—time 1.000 1 Professional values—advances field of pharmacy 1.000
2 Support—resources 0.697 1.000 2 Organizational values—best care for patients 0.640 1.000
3 Expectation 0.573 0.636 1.000 3 Organizational values—improves patient outcomes 0.661 0.677 1.000
4 Reward 0.486 0.531 0.493 1.000 4 Professional values—what pharmacies should be doing 0.730 0.638 0.645 1.000
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points higher among independently owned pharmacies
(p = 0.041).
Hurdle regression: equation 2
Hypothesis 1
Findings from the second equation of the hurdle regres-
sion indicated that a one-unit increase an implementa-
tion climate score was associated with a 5.05 increase in
implementation of CMRs per high-risk patients holding
all else constant (p = 0.001). The predicted number of
CMRs per high-risk patients for pharmacies with the
median implementation climate score (9.14) was 16.21
compared to 28.10 for pharmacies with an implementa-
tion climate score at the 75th percentile (12.50).
Hypothesis 2
Similarly, implementation of CMRs per high-risk pa-
tients was positively associated with innovation-values fit
score (p < 0.001). The predicted number of CMRs per
high-risk patients for pharmacies with the median
innovation-values score (13.07) was 32.09 compared to
59.36 for pharmacies with an implementation climate
score at the 75th percentile (14.68).
Hypothesis 3
The marginal effect of innovation-values fit on the num-
ber of CMRs per high-risk patients increased as imple-
mentation climate score increased (Fig. 3).
Hypothesis 4
In terms of patients’ needs and resources, pharmacies lo-
cated in rural locations were associated with lower imple-
mentation of CMRs per high-risk patients (p = 0.006).
Conversely, pharmacies that participate in the 340B Drug
Pricing Program were associated with higher implementa-
tion (p = 0.026). For available resources, pharmacies with a
clinical pharmacist were associated with higher implemen-
tation (p = 0.002). However, an increase in total staff was as-
sociated with a 1.98 decrease in implementation of CMRs
per high-risk patients (p < 0.001). For available resources,
implementation of CMRs per high-risk patients was
positively associated with experience with NC-CPESN
(p = 0.004), past performance with NC-CPESN (p < 0.001),
and participation in Medicare Part D MTM (p = 0.003).
No significant differences in implementation were found
based on structural characteristics.
Discussion
In this study, we used the organizational theory of
innovation implementation effectiveness [18–20] to test
organizational factors that influence implementation ef-
fectiveness of a community pharmacy medication man-
agement intervention. Consistent with our hypothesis,
we found that key constructs from this theory, such as
implementation climate and innovation-values fit, were
positively associated with implementation and program
reach of NC-CPESN. To our knowledge, only one other
quantitative study has examined the relationship be-
tween implementation climate and implementation
Table 3 Factor loadings from the rotated factor structure matrix for implementation climate and innovation-values fit scales
Implementation climate items Factors
1 2 3 4
[Support—time] Our pharmacy allocates sufficient time to delivering
enhanced pharmacy services.
0.523 − 0.293 − 0.396 0.644
[Support—resources] Our pharmacy devotes adequate resources to
implementing enhanced pharmacy services.
0.543 − 0.296 − 0.218 − 0.055
[Expectation] In our pharmacy, we are expected to participate in the
delivery of enhanced pharmacy services.
0.487 − 0.037 0.565 0.114
[Reward] In our pharmacy, individuals receive recognition for
participating in the delivery of enhanced pharmacy services.
0.442 0.110 − 0.216 0.040
Innovation-values fit items Factors
1 2 3 4
[Professional values] Delivering enhanced pharmacy services is what
pharmacies should be doing.
0.498 − 0.224 0.251 − 0.232
[Organizational values] Delivering enhanced pharmacy services is
consistent with providing the best care possible for our patients.
0.501 − 0.068 − 0.128 0.369
[Organizational values] Delivering enhanced pharmacy services is
important for improving health outcomes for our patient population.
0.506 0.406 − 0.308 − 0.096
[Professional values] Delivering enhanced pharmacy services is
important for advancing the field of pharmacy.
0.495 0.185 0.295 0.371
Factor loadings in boldface indicate double loading on two or more factors. Factor loadings in italics indicate the factor on which the item was placed
Turner et al. Implementation Science  (2018) 13:105 Page 9 of 13
effectiveness in healthcare [31], and no other study in
healthcare has explored the direct and indirect effects of
innovation-values fit on implementation effectiveness.
Contrary to our hypotheses of contextual factors, only
certain factors, such as having a clinical pharmacist on
staff, participation in Medicare Part D MTM, or 340B
Drug Pricing Program, predicted both implementation
and program reach. We were also surprised that 40.8%
of the community pharmacies participating in the study
did not have implementation activity within the study
period. We describe potential reasons for this below.
We hypothesized that implementation climate and
innovation-values fit would be positively and directly
associated with implementation effectiveness, which was
supported by our findings. These findings suggest that
implementation climate and innovation-values fit were
useful measures for predicting implementation and pro-
gram reach. Further studies are needed to test whether
these measures are predictive of implementation effect-
iveness across a wider variety of community pharmacy
medication management programs. For example, we
learned from the previous qualitative work that NC-CPESN
community pharmacy staff worked collaboratively to imple-
ment CMRs. For other medication management programs,
organizations may rely on a single staff member to deliver
the intervention. In such cases, individual-referenced
measures of implementation climate [32] may be more
valid than group-referenced items.
The study results also supported the hypothesis that
innovation-values fit moderates the effect of
Table 4 Parameter estimates from hurdle regression of NC-CPESN implementation and program reach of NC-CPESN implementation
Characteristics Equation 1: binary (implementation)
AMEa,b (SE)
Equation 2: positives (program reach)
AMEa (SE)
Key independent variables
Implementation climated 2.65 (1.85 × 103)c*** 5.05 (1.5)**
Innovation-values fitd 2.17 (1.041 × 102)* 11.79 (3.170)***
Patient needs and resources
Rural location −0.77 (0.016) − 12.81 (4.658)**
Clinical factors −0.04 (3 × 104) − 0.14 (0.11)
Social factors −0.06 (3 × 104) − 0.10 (0.10)
340B participation 5.70 (3.50 × 102)* 12.80 (5.760)*
Proportion of high-risk patients 0.00 (0.00)* –
Log of high-risk patients – (exposure)
Available resources
Presence of a clinical pharmacist 9.86 (4.75 × 102)* 32.33 (10.670)***
Total number of staff − 0.31 (2.6 × 103) − 1.98 (0.550)***
Presence of pharmacy student or resident 6.86 (6.37 × 102) 14.55 (7.273)
Access to knowledge about the intervention
Amount of experience with NC-CPESN (months) 0.43 (1.3 × 103)** 1.57 (0.610)***
Past performance with NC-CPESN 0.46 (1.3 × 102)*** 0.10 (0.031)***
Participation in Medicare Part D MTM 18.73 (6.246 × 102)** 28.05 (13.83)*
Structural characteristics
Independent pharmacy 4.14 (2.02 × 102)* 0.43 (5.6)
Low prescription volume 1.08 (0.032) 7.23 (7.21)
Established pharmacy 2.02 (0.015) 4.14 (7.46)
Alpha – 0.56 (7.08 × 102)**
Constant − 21.04 (4.79)*** − 14.03 (1.383)***
Observations 180 104
Significance of hurdle regression: *p < 0.05, **p < 0.01, ***p < 0.001
aAME, average marginal effect
bEffect sizes for the stage 1 model are in percentage points; for example, 9.86 for presence of clinical pharmacist indicates that the probability of implementing
NC-CPESN was 9.86 percentage points higher for pharmacies that have a clinical pharmacist
cAny standard errors that were carried out to the ten-thousandths place value or smaller are represented in scientific notation
dEquation 1 and 2 include an interaction term (implementation climate*innovation-values fit), which is represented in the AME of implementation climate and
innovation-values fit
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implementation climate on implementation effective-
ness, indicating that implementation climate and
innovation-values fit work in concert. Our findings also
suggest that innovation-values fit may have a greater ef-
fect on implementation climate at lower levels of imple-
mentation climate and that the effect may diminish at
higher levels of implementation climate (Fig. 2). Further
research is needed to establish whether there are dimin-
ishing returns to the effect of innovation-values fit on
implementation climate and whether the relationship de-
pends on the outcome of interest, i.e., presence of
implementation activity versus level of implementation
activity (e.g., program reach). Additionally, future research is
needed to determine what factors are positively associated
with implementation climate and innovation-values fit in
pharmacy medication management programs. For ex-
ample, the organizational theory of innovation implemen-
tation effectiveness [18–20] maintains that management
support is an antecedent of implementation climate, but
there has been little quantitative research on how to
operationalize the construct of management support. Re-
cently, researchers have developed a measure for imple-
mentation leadership to assess which leadership qualities
are correlated with successful implementation [44]. Future
studies could assess whether implementation leadership is
associated with implementation climate. This has practical
importance because identifying the leadership behaviors
and traits associated with effective implementation could
provide guidance to pharmacy leaders on how to de-
velop a supportive climate for medication manage-
ment program implementation.
Contrary to our hypotheses, we found that only certain
aspects of the organizational context affected both imple-
mentation and program reach. For example, none of the
structural characteristics (e.g., pharmacy type, established
pharmacy) were significantly associated with both imple-
mentation and program reach. Additional research is
needed to determine whether there are other structural
characteristics that may be associated with successful im-
plementation of pharmacy medication management pro-
grams. Consistent with our hypotheses, access to
knowledge about the intervention (e.g. participation in
Medicare Part D MTM), patient needs and resources (e.g.,
proportion of high-risk patients, participation in 340B Drug
Pricing Program), and availability of certain resources (e.g.,
clinical pharmacist) positively affect implementation effect-
iveness. Prior theory suggests that establishing an imple-
mentation climate for one intervention may help facilitate
implementation climate for a similar intervention [29]. It is
possible that community pharmacies use similar strategies
to support MTM and medication management services im-
plementation (e.g., staff training on motivational interview-
ing)—explaining the positive association between Medicare
Part D MTM and NC-CPESN implementation. Future
studies should use qualitative methods to explore the im-
plementation strategies that community pharmacies estab-
lish to foster a climate for medication management services
and whether these strategies facilitate implementation of
similar interventions. Such studies could be used to develop
implementation guidance to support community pharma-
cies participating in multiple medication management pro-
grams simultaneously, which may increase as pharmacy
participation in alternative payment models grows. We also
found that having a clinical pharmacist on staff was an im-
portant predictor of implementation effectiveness. How-
ever, clinical pharmacists’ roles and the amount of time
available for clinical services can vary widely across com-
munity pharmacies [34, 35]. Future qualitative studies are
needed to describe how community pharmacies define the
job roles of clinical pharmacists, how much time clinical
pharmacists are given for non-dispensing activities, and
whether such differences are perceived to impact the effect-
iveness of clinical pharmacists.
Fig. 2 Plot of marginal effect of innovation-values fit and
implementation climate score for Equation 1
Fig. 3 Plot of marginal effect of innovation-values fit and
implementation climate score for Equation 2
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Unexpectedly, we found that about 40% of the phar-
macies participating in this study did not implement a
CMR during the study period. From a recent qualitative
study we conducted, we found that many of the pharma-
cies in the NC-CPESN program struggled not necessar-
ily with conducting a CMR but with documenting a
CMR [41]. Most pharmacies indicated that they received
sufficient training on the documentation system but
struggled with finding the time to document the CMR
and found the process to be burdensome. Some pharma-
cies described having to hire additional staff to assist
with documentation or having staff work overtime to
keep up with documentation. To address this need,
CCNC has updated the templates for CMR documentation
and made improvements to the documentation system it-
self [45]. Future studies are needed to test whether the new
system reduces the amount of time needed for documenta-
tion and improves NC-CPESN pharmacies ability to docu-
ment CMRs. Such research would have applicability not
only for NC-CPESN but also for other programs that re-
quire documentation of medication management services,
such as the Medicare Part D MTM program.
Limitations
This study had several limitations. First, since we mea-
sured implementation climate, innovation-values fit, and
implementation effectiveness at the same time, we cannot
establish the causal order. Second, the generalizability of
our findings is limited by: (1) only having data at one time
point; (2) conducting the study in NC, the first CPESN
organization. Future studies are needed to examine imple-
mentation of medication management programs over time
and across settings. Third, our measures of implementa-
tion effectiveness, implementation and program reach
among high-risk patients, are limited in scope and do not
assess other important aspects of implementation effect-
iveness such as fidelity of CMR delivery. Future studies
are needed to establish additional measures of implemen-
tation effectiveness (e.g., conducting site observations to
measure CMR fidelity). Finally, we did not measure other
determinants of implementation effectiveness including
the presence of an innovation champion or variability in
implementation climate perceptions [18–20]. Future
studies should develop and test these measures in phar-
macy medication management programs.
Conclusions
As more state Medicaid programs adopt pharmacist-led
medication management programs, it is important to
identify what organizational determinants promote effective
implementation of these programs. Our study supported
the use of the organizational theory of innovation imple-
mentation effectiveness to identify organizational determi-
nants that are associated with effective implementation
(e.g., implementation climate and innovation-values fit)
[18–20]. Unlike broader environmental factors or structural
characteristics (e.g., pharmacy type), implementation cli-
mate and innovation-values fit are modifiable factors and
can be targeted through intervention—a finding that is
important for community pharmacy practice. Add-
itional research is needed to determine what implemen-
tation strategies can be used by community pharmacy
leaders and practitioners to develop a positive imple-
mentation climate and innovation-values fit for medica-
tion management programs.
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